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Detection of heterozygous large deletions in the
antithrombin gene using multiplex polymerase chain
reaction and denatured high performance liquid
chromatography
Large gene rearrangements such as dele-tions, duplications and inversions rep-resent a considerable proportion of
mutations causing hereditary disorders.
Most methods applied for screening of dis-
ease-causing mutations are polymerase
chain reaction (PCR)-based and enable the
easy detection of sequence alterations such
as point mutations and small deletions/inser-
tions. However, these techniques are not
capable of detecting large heterozygous
autosomal deletions because of the presence
of a second normal allele. Non-PCR-based
methods such as Southern blotting, fluores-
cent in situ hybridization (FISH), or compara-
tive genomic hybridization (CGH)1,2 are
labor-intensive, require large amounts of
DNA and have a low throughput. Other
methods based on quantitative differentia-
tion such as real-time PCR, multiplex ampli-
fiable probe hybridization (MAPH), multi-
plex ligation-dependent probe amplification
(MLPA) or quantitative multiplex PCR of
short fluorescent fragments (QMPSF)3-7 are
limited by the requirement of multiple sets
of specific primers, probes and dyes that
greatly increase costs. Furthermore, poly-
morphisms or rare variants at the probe tar-
get site may prevent probe hybridization
and ligation and can lead to false positive
results. 
To overcome these restrictions we estab-
lished a new approach for the detection of
heterozygous large deletions based on a
multiplex PCR followed by denatured high
performance liquid chromatography
(DHPLC) analysis.8-10 We used the autosomal
antithrombin gene (AT) as a model for test-
ing the new approach. Antithrombin (AT) is
a major physiological inhibitor of blood
coagulation and its deficiency greatly
increases the risk of recurrent thromboem-
bolism.11
AT is located on the long arm of chromo-
some 1 (q23-25) and comprises seven exons
spanning 13,477 bp of genomic DNA. The
mutation profile in AT is heterogeneous,
including nonsense and missense mutations
as well as small deletions/insertions,12,13
while large deletions are rare.14-16 In our
cohort of 24 AT deficient patients we were
unable to find a mutation in seven patients
by standard mutation screening. We, there-
fore, proposed that at least some of these
patients might carry heterozygous large
deletions of one or more exons. Analyzing
these patients with the new multiplex
PCR/DHPLC-based technique we identified
four large deletions involving exons 1, 2, 7
and the whole AT gene.
Design and Methods
Patients
Twenty-four unrelated patients with  type I
AT deficiency (low AT antigen level and activ-
ity; mean values of 13.08 mg/dL and 48.97%,
respectively) were included in this study. All
patients had suffered from thromboembolic
events. AT deficiency was confirmed by
repeated measurement of both AT antigen by
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The present study reports a method for the easy, rapid and cost effective detection of
heterozygous large deletions. As a model gene all exons of the antithrombin gene were
amplified in a one tube multiplex polymerase chain reaction (PCR) and the products
separated according to their size by reverse-phase ion-pair high performance liquid
chromatography. A significant reduction in the height of a peak in the proband’s sam-
ple compared to in the control indicates the presence of a large deletion of the corre-
sponding allele. Using this approach we identified heterozygous deletions in four
patients: the deletions affected exons 1  and 2, exon 7 and the whole antithrombin
gene.
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radial immunodiffusion (NOR-Partigen Immundiffu-
sionsplatte Antithrombin, Dade Behring, Marburg,
Germany)  and activity by factor Xa-based chromogenic
substrate assay (Coamatic LR Antithrombin, Haemo-
chrom Diagnostika, Essen, Germany) according to the
manufacturers’ recommendations. Patients with
reduced AT activity potentially due to confounding liver
disease or acute thrombosis were excluded from the
study (four patients). Informed consent was obtained
from all index patients and their family members. In 17
patients nonsense or missense mutations, small dele-
tions or insertions were identified by direct sequencing
of AT (data not shown). In the remaining seven patients,
in whom no mutations were identified by conventional
sequencing approach, large gene rearrangements were
proposed to be the cause of the deficiency. 
Antithrombin gene analysis
DNA isolation: High molecular genomic DNA was iso-
lated from peripheral whole blood by the standard salt-
ing out procedure described by Miller et al.17 DNA con-
centrations were standardized to 100 ng/µL.
Multiplex PCR: All seven exons and flanking introns of
AT were amplified  by semi-quantitative multiplex PCR.
The primers (Table 1) were designed to allow amplifica-
tion at the same annealing temperature (55°C) and giv-
ing rise to amplicons which differed by at least 17 bp.
An HGH fragment (exons 2 and 3) 434bp long was
amplified together with AT as an internal PCR control.
A common master mix was used to achieve maximal
equivalent amplification conditions. Amplifications
were performed using 100 ng of genomic DNA, 20 pmol
of each primer,  50 µM of each of the four types of
dNTP, and 2.5 U of AmpliTaq-Gold DNA polymerase
(PE Applied Biosystems) in a total volume of 50 µL con-
taining 1×GeneAmp PCR buffer with 1.5 mM MgCl2
(PE Applied Biosystems). To keep the PCR reaction in
the linear exponential phase, 25 cycles of touch-down
PCR were performed under the following conditions:
initial denaturation at 95°C for 5 min followed by
denaturation at 95°C for 30 sec., annealing under reduc-
tion of temperature from 61°C to 55°C by 3°C every 3
cycles for 30 sec, extension at 72°C for 30 sec and final
extension for 5 min at 72°C. 
DHPLC
Aliquots of 10 µL of the multiplex PCR product were
injected in a semi-automated high throughput DHPLC
system WAVE (Transgenomic Ltd., Omaha, USA).
Separation was performed on a DNAsep cartridge (Ion
pair reverse phase C18 column - Transgenomic Ltd.) at
a constant oven temperature of 50°C and with UV
detection at 260 nm. The mobile phase was 0.1 M tri-
ethylammonium acetate (TEAA) solution in water, pH7
(buffer A) and 0.1 M TEAA and 25% acetonitrile (buffer
B). The PCR product was eluted at a flow rate of 0.9
mL/min with a gradient of 40 - 72% for buffer B over 20
min. Navigator 1.5.3. Software (Transgenomic Ltd.) was
used for data analyses. The chromatograms of investi-
gated patients’ samples were superposed on those of
the normal control and normalized according to the
internal HGH control peak. The ratio for each peak was
calculated (peak height of the sample/ peak height of
control). Ratios between 0.4 and 0.6 indicated the pres-
ence of a large gene deletion.
Results and Discussion
In four patients (numbers 1, 2, 6 and 7) the ratio of the
peaks’ height for at least one peak was in the range of
0.4–0.6, indicating a heterozygous deletion in the corre-
sponding exon(s) (Table 2). In patient 1, a ratio of 0.53
was observed in exon 7, pointing to a deletion of this
exon (Figure 1A). This result was confirmed in three
other members of the family. Patient 7 exhibited a dele-
tion of exons 1 and 2 producing ratios of 0.57 and 0.60,
respectively (Figure 1C). In patients 2 and 6, an approx-
imately 50% reduction of the height in all peaks was
found (ratios 0.42–0.60) reflecting a deletion of the
whole gene (Figure 1B, D). This deletion was confirmed
in another AT-deficient relative of patient 2. In the
remaining three samples (numbers 3, 4 and 5) the ratios
of the peaks’ height for all fragments were in the range
between 0.85 and 1.00 and excluded a large deletion as
a cause of the AT deficiency.
To validate the sensitivity of the method we exam-
ined all 17-AT deficient patients in whom point muta-
tions or small deletions and insertions had been found
to be causative for the disorder and 20 healthy donors.
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Table 1. Amplification primer sequences for AT and HGH.
PCR region Primer sequence (5' to 3') Annealing Product 
temperature (°C) Size (bp)
AT-Exon1F ctg tcc tct gga acc tct gcg 55 273
AT-Exon1R ttt gac tgt aac tac cag gga ga 55
AT-Exon2F ctc tgc ttt act ggg gca ac 55 580
AT-Exon2R agc cca aag gtg ctc cta ac 55
AT-Exon3F act gag gtg gct att agt cag ag 55 373
AT-Exon3R aat att gag tgg aga gga aga a 55
AT-Exon4F tga ata gca cag gtg agt agg t 55 236
AT-Exon4R gta agc tga aga gca aga gga a 55
AT-Exon5F tgt ctg tgt caa taa cta tcc tcc t 55 607
AT-Exon5R tcc aac tct tcc act ttt ggt c 55
AT-Exon6F agc caa ctt tct ccc atc tc 55 253
AT-Exon6R ggt ttt gga gag ggc tgt at 55
AT-Exon7F ggc aga gtg gct aat tta gtt tta 55 327
AT-Exon7R att tca aat gca gag tcc att tat 55
HGH-Exon2-3F tgc ctt ccc aac cat tcc ctt 55 434
HGH-Exon2-3R cca ctc acg gat ttc tgt tgt gtt tc 55
Primer sequences do not overlap with any known single nucleotide
polymorphisms as screened against the SNP database
(http://www.ncbi.nlm.nih.gov/SNP).
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The ratio in all samples for all exons was in the range
between 0.9 and 1.0, indicating the absence of large
deletions (data not shown). Large deletions were detected
only in patients without point mutations. The repro-
ducibility of the technique was controlled by repeating
the multiplex amplification of samples from a normal
control and a patient with whole gene deletion (patient
number 2) ten times. This showed high reproducibility
with a standard deviation ranging from 0.0049 to
0.0087. In addition the detected deletion in family 2
(Table 2) segregated well with the clinical phenotype; in
particular the brother who does not have a reduced AT
level does not carry the deletion. The large deletions
represent 16.6% of the mutations in our cohort of
patients with AT deficiency, which differs from the
9.2% reported in the AT mutation database13,16 or that
estimated to be about 5.5.% in the Human Gene
Mutation database. This fact poses the question  of
whether the proportion of large AT deletions may be
more common than currently thought, but remain
underestimated because of the difficulties in their detec-
tion. Gene alterations can occur through many mecha-
nisms, one of which is homologous recombination
between Alu repeats or longer repetitive L1 fragments.
The high number of ten such elements in AT gene18,19
may contribute to the formation of large deletions in
this gene. In the patients with no detectable disease-
causing mutations in AT, we cannot exclude mutations
located deeply within the introns and affecting splicing
since the RNA was not analyzed. It must also be consid-
ered that despite the stringent inclusion criteria these
patients may have acquired rather than inherited AT
A. Pavlova et al.
Figure 1. DHPLC chromatograms of four-AT
deficient patients with partial and whole
gene deletions. The solid line (in black) rep-
resents the normal control. The dotted line
(in red) represents the examined sample.
All samples are superposed and normal-
ized according to the internal control peak
of HGH. A. In sample 1 the height of only
exon 7 is half that of the normal control,
indicating a deletion of this exon. B.
Sample 2 shows deletion of the whole
gene; the heights of all exon peaks are half
those of the control peaks. C. Deletion of
exons 1 and 2 were found in sample 6. D.
Deletion of the whole gene was also found
in sample 7. Vertical arrows indicate the
reduced peak corresponding to a deletion.
Table 2. AT antigen and AT activity values and the  ratio of peak heights compared to the normal control in patients with and without
deletions, after normalization to 1.00. 
Family # Patients AT:Ag AT Activity Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Results
(21-30 mg/dL) (86-122%)
Family 1 Index patient 17,5 47 0.99 0.98 1.00 0.98 1.00 1.00 0.53 Exon 7 del.
Grand father 15,3 42 0.97 0.98 0.96 0.99 0.92 0.98 0.49 Exon 7 del.
Mother 16,2 44 1.00 0.95 0.99 0.85 0.96 0.99 0.54 Exon 7 del.
Brother of Mother 15,8 40 0.99 0.92 0.98 0.96 0.90 0.97 0.50 Exon 7 del.
Brother 28.1 98 0.98 0.99 1.00 0.97 1.00 0.99 0.98 No del.
Family 2 Index patient 13,3 67 0.53 0.52 0.42 0.56 0.54 0.56 0.51 Whole gene del.
Mother 12.0 44 0.54 0.47 0.42 0.52 0.50 0.57 0.50 Whole gene del.
Family 3 Index patient 17,3 60 1.00 1.00 0.98 0.98 1.00 0.99 0.98 No del.
Family 4 Index patient 11,2 30 0.85 0.98 1.00 0.90 0.99 0.96 1.00 No del.
Family 5 Index patient 12.8 67 0.98 0.99 0.99 1.00 0.91 0.98 1.00 No del.
Family 6 Index patient 14,8 43 0.57 0.59 0.98 1.00 0.98 1.00 0.86 Exons 1-2 del.
Family 7 Index patient 11,4 39 0.52 0.61 0.50 0.53 0.54 0.56 0.56 Whole gene del.
Normal values of AT antigen and activity are shown in  brackets. AT:Ag : antithrombin antigen; del. :deletion.   
A: Patient 1
C: Patient 6
HGH
Ex: 4 6 1 7 3 2 5 Ex: 4 6 1 7 3 2 5
Ex: 4 6 1 7 3 2 5Ex: 4 6 1 7 3 2 5
HGH HGH
HGH
D: Patient 7
B: Patient 2
deficiency. In conclusion, screening for large deletions in
AT will complete the genetic analysis of AT, thus
improving differentiation between inherited and
acquired AT deficiency and also aiding genetic counsel-
ing of affected families. The method described in this
study is a rapid, simple and sensitive screening test for
AT rearrangements.
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